Their proprietary technology allows for diversification of the portfolio of different DNA and RNA detection purposes like for respiratory, blood-borne, and urine-based diseases, and they are pioneers of next-generation molecular diagnostics solutions bringing Nobel-Prize winning PCR medical tests straight to patients. Their first product, STD Multitest, is ready to scale up production and start worldwide sales, while their next-generation molecular diagnostics Multitest platform is an innovative tool for launching a family of rapid molecular tests, including the Multitest COVID-19, which combines the ease of use of rapid tests and the diagnostic accuracy of laboratory PCR.